About anbio biotechnology - NNNN
Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany.
NNNN At a Glance
Anbio Biotechnology
Wilhelm Gutbrod Street, 21B
Frankfurt, Hessen 60437
| Phone | 49-16-96247281 | Revenue | 8.85M | |
| Industry | Medical Specialties | Net Income | 2.57M | |
| Sector | Health Technology | 2024 Sales Growth | 22.013% | |
| Fiscal Year-end | 12 / 2025 | Employees | 27 | |
| View SEC Filings |
NNNN Valuation
| P/E Current | 590.445 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
NNNN Efficiency
| Revenue/Employee | 327,918.399 |
| Income Per Employee | 95,062.269 |
| Receivables Turnover | 8.03 |
| Total Asset Turnover | 0.478 |
NNNN Liquidity
| Current Ratio | 10.712 |
| Quick Ratio | 10.712 |
| Cash Ratio | 6.797 |
NNNN Profitability
| Gross Margin | 71.903 |
| Operating Margin | 24.378 |
| Pretax Margin | 28.99 |
| Net Margin | 28.99 |
| Return on Assets | 13.851 |
| Return on Equity | 15.022 |
| Return on Total Capital | 14.418 |
| Return on Invested Capital | 15.022 |
NNNN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |